|
|
|
篇目详细内容 |
|
【篇名】 |
Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases? |
|
【刊名】 |
Frontiers of Medicine in China |
|
【刊名缩写】 |
Front. Med. China |
|
【ISSN】 |
1673-7342 |
|
【EISSN】 |
1673-7458 |
|
【DOI】 |
10.1007/s11684-010-0010-0 |
|
【出版社】 |
Higher Education Press and Springer-Verlag Berlin
Heidelberg |
|
【出版年】 |
2010 |
|
【卷期】 |
4
卷1期 |
|
【页码】 |
46-53
页,共
8
页 |
|
【作者】 |
Xu WANG MS;
Xiao-Wei GONG MD, PhD;
Yu-Hua LI PhD;
Yong JIANG MD, PhD;
|
|
【关键词】 |
mitogen-activated protein kinase; drug target; inhibitor; signal transduction; disease |
【摘要】 |
|
Mitogen-activated protein kinase (MAPK) signaling pathway, one of the most important signaling pathways in eukaryotic organism, is involved in multiple cellular events such as cell growth, differentiation, and apoptosis. MAPK is of great importance to the normal function of organisms, while its dysfunction results in various diseases. So far, inhibitors specifically against each subfamilies of MAP kinase have been developed, while more endeavors are needed to discover the compounds selectively targeting a particular subfamily member. Most of the kinase inhibitors exert their functions in an ATP-competitive way or a non-ATP-competitive way. Further studies on the effective mechanism of the MAPK inhibitors and their therapeutic roles in the treatment of diseases are helpful for the illumination of MAP kinase function, the development of novel inhibitors, and the therapy of diseases caused by the dysfunction of the MAPK pathway. |
|
